Iran Press/ Iran News: 'Payam Tabarsi', the main researcher of the Iranian-Australian 'Spicogen' vaccine study project said: "After successfully passing the third stage of the human test of the 'Spicogen' corona vaccine, this vaccine will enter Iran's vaccine basket from the end of October 2021."
Tabarsi added: "This project is subject to approval and obtaining a license from the Food and Drug Administration, which seems to be approved according to the existing conditions."
The main researcher of the Iranian-Australian vaccine study project 'Spicogen' announced the monthly capacity of Sinogen Pharmaceutical Company to produce this vaccine as three million doses.
Spicogen vaccine, a joint production of Iran and Australia, has the technology to make recombinant proteins, and if the clinical trial is successful, this vaccine will be produced in Iran.
The pre-clinical phase and the first phase of the clinical trial of the 'Spicogen' vaccine were performed in Australia and after it was approved by Australia's Ministry of Health, the Ministry of Health of Iran accepted it and the second phase of the human test was performed and the third phase Is done.
207/224
Read More:
17th shipment of COVID-19 vaccine purchased by IRCS enters Iran
IRCS imports 11th COVID-19 vaccine shipment to Iran
COVID vaccine distribution to reach 10 million by Friday
